196 related articles for article (PubMed ID: 26396095)
41. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
[TBL] [Abstract][Full Text] [Related]
42. Effect of two prophylactic bolus vitamin D dosing regimens (1000 IU/day vs. 400 IU/day) on bone mineral content in new-onset and infrequently-relapsing nephrotic syndrome: a randomised clinical trial.
Muske S; Krishnamurthy S; Kamalanathan SK; Rajappa M; Harichandrakumar KT; Sivamurukan P
Paediatr Int Child Health; 2018 Feb; 38(1):23-33. PubMed ID: 28466679
[TBL] [Abstract][Full Text] [Related]
43. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.
Winer KK; Sinaii N; Reynolds J; Peterson D; Dowdy K; Cutler GB
J Clin Endocrinol Metab; 2010 Jun; 95(6):2680-8. PubMed ID: 20392870
[TBL] [Abstract][Full Text] [Related]
44. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
Shane E; Rodino MA; McMahon DJ; Addesso V; Staron RB; Seibel MJ; Mancini D; Michler RE; Lo SH
J Heart Lung Transplant; 1998 Nov; 17(11):1089-96. PubMed ID: 9855448
[TBL] [Abstract][Full Text] [Related]
45. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy.
Loddenkemper K; Bohl N; Perka C; Burmester GR; Buttgereit F
Rheumatol Int; 2006 Feb; 26(4):331-6. PubMed ID: 15887044
[TBL] [Abstract][Full Text] [Related]
46. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.
Sambrook P; Birmingham J; Kelly P; Kempler S; Nguyen T; Pocock N; Eisman J
N Engl J Med; 1993 Jun; 328(24):1747-52. PubMed ID: 7684512
[TBL] [Abstract][Full Text] [Related]
47. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
[TBL] [Abstract][Full Text] [Related]
48. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
49. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
Tomida K; Hamano T; Mikami S; Fujii N; Okada N; Matsui I; Nagasawa Y; Moriyama T; Ito T; Imai E; Isaka Y; Rakugi H
Bone; 2009 Apr; 44(4):678-83. PubMed ID: 19111635
[TBL] [Abstract][Full Text] [Related]
50. [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
Wang QH; Wu HX; Huang YL; Xue J; Yang XY; Zhu L; Wen LH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1888-91. PubMed ID: 19040000
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
52. Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women.
Kharroubi A; Saba E; Smoom R; Bader K; Darwish H
Arch Osteoporos; 2017 Dec; 12(1):13. PubMed ID: 28124221
[TBL] [Abstract][Full Text] [Related]
53. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers.
Gallagher JC; Rapuri PB; Haynatzki G; Detter JR
J Clin Endocrinol Metab; 2002 Nov; 87(11):4914-23. PubMed ID: 12414850
[TBL] [Abstract][Full Text] [Related]
54. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
[TBL] [Abstract][Full Text] [Related]
55. Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients.
Huraib S; Abu-Aisha H; Abed J; Al Wakeel J; Al Desouki M; Memon N
Am J Nephrol; 1997; 17(2):118-23. PubMed ID: 9096441
[TBL] [Abstract][Full Text] [Related]
56. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
Indridason OS; Quarles LD
Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
[TBL] [Abstract][Full Text] [Related]
57. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
58. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
59. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Deane A; Constancio L; Fogelman I; Hampson G
BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
[TBL] [Abstract][Full Text] [Related]
60. [Effects of Xianling Gubao capsules for the treatment of bone loss induced by glucocorticoid].
Wu JJ; Wen LP; Wu YG; Shen Q; Han Y
Zhongguo Gu Shang; 2009 Mar; 22(3):193-5. PubMed ID: 19366101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
